Integrated DNA Technologies Opens Business Unit and Launches New Products
News May 20, 2008
Integrated DNA Technologies (IDT) has announced that it has opened a new business unit dedicated to the manufacture of oligonucleotides for use in diagnostic products.
The company has been awarded ISO 13485:2003 certification at its Coralville facility, for its new business unit called “Clinical and Commercial Manufacturing” (CCM).
This globally recognized certificate confirms that IDT meets the rigorous standards required for the supply of custom manufacturing/processing services, customer support and sales distribution of molecular biology products for molecular in vitro diagnostic devices and licensed nucleic acid tests. This covers its synthetic oligonucleotides as well as the associated reagents and consumables.
Bill Jones, Director of Quality Assurance for IDT, said, “This dedicated manufacturing suite, with its additional ISO 13485 certification and compliance with FDA 21 CFR Part 820 QSR/cGMP, positions IDT to better serve both our current and future clinical/medical device customers. It will also be important for other commercial customers with applications that need a higher level of process control and compliance.”
The ISO 13485:2003 certification and subsequent registration of the facility with the FDA, follows a series of audits - carried out by BSI Management Systems, a prominent quality management systems registrar - requiring on-site assessments, examinations of IDT's documented procedures, and an audit of overall operations.
System quality is then monitored through periodic surveillance audits of IDT's processes, by BSI Management Systems. As a result the ISO 13485:2003 certification provides a clear, recognized, and highly respected standard for quality management in the highly regulated clinical/medical market.
In addition, the company announced the availability of an entire suite of fluorescent dyes and quenchers that can be used in diagnostic products, which require no additional licensing from IDT or third parties.
The so-called Freedom Dye program currently provides ten fluorescent dyes and companion dye-quenchers that can be used by CCM clients as ready replacements for royalty-bearing dyes and quenchers in-licensed from third parties.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.